CN109248180A - 南洋山苏水萃物的用途 - Google Patents
南洋山苏水萃物的用途 Download PDFInfo
- Publication number
- CN109248180A CN109248180A CN201810763544.1A CN201810763544A CN109248180A CN 109248180 A CN109248180 A CN 109248180A CN 201810763544 A CN201810763544 A CN 201810763544A CN 109248180 A CN109248180 A CN 109248180A
- Authority
- CN
- China
- Prior art keywords
- sushui
- nan yang
- shan
- nan
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 235000004347 Perilla Nutrition 0.000 title abstract 4
- 244000124853 Perilla frutescens Species 0.000 title 1
- 238000000605 extraction Methods 0.000 claims abstract description 38
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims abstract description 12
- 208000002353 alcoholic hepatitis Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 3
- 241000229722 Perilla <angiosperm> Species 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 12
- 230000003908 liver function Effects 0.000 description 10
- 210000005229 liver cell Anatomy 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000000470 constituent Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241001453169 Asplenium Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 241000134854 Aspleniaceae Species 0.000 description 1
- 241001312267 Asplenium australasicum Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
一种南洋山苏水萃物的用途,用以制备治疗酒精性肝炎的药物,其中,该南洋山苏水萃物以水作为萃取溶剂,于115~125℃的温度、0.35~0.5 Kg/cm2G的压力下萃取一个南洋山苏样品1.5~3小时所获得。
Description
技术领域
本发明涉及一种南洋山苏水萃物的用途,特别涉及一种南洋山苏水萃物应用于制备治疗酒精性肝炎的药物的用途。
背景技术
酒精性肝炎(alcoholic hepatitis)是指长期摄取酒精(乙醇)所造成的酒精性肝疾病,主要的临床症状为急性黄疸(acute jaundice)、发烧(fever)、体重减轻(weight)等。严重的酒精性肝炎患者可能会出现腹水(ascites)及肝脑病变(hepatic encephalopathy)等并发症(complication),甚至导致肝硬化(hepatic cirrhosis)。一般而言,临床上以皮质类固醇(corticosteroids)来治疗酒精性肝炎的重症患者,然而其试验结果的变异性大,且无法适用于有肠胃道出血或对类固醇过敏的病人,因此仍需要提供一种南洋山苏水萃物的用途,以改善前述的问题。
发明内容
为解决上述问题,本发明提供一种南洋山苏水萃物的用途,将萃取自南洋山苏的活性成分,应用于制备治疗酒精性肝炎的药物。
本发明的南洋山苏水萃物的用途,应用于制备治疗酒精性肝炎的药物,其中,该南洋山苏水萃物以水作为萃取溶剂,于115~125℃的温度、0.35~0.5Kg/cm2G的压力下萃取一个南洋山苏样品1.5~3小时所获得,较佳地,该南洋山苏水萃物能够以口服方式投予一个所需个体,且该南洋山苏水萃物的每天投予该所需个体的剂量为2.5毫升/公斤体重;如此通过萃取自南洋山苏的活性成分,可以降低乙醇所造成的肝功能指数升高的现象及减缓乙醇所造成的肝细胞坏死的现象,因而可以应用于制备治疗酒精性肝炎的药物,为本发明的功效。
附图说明
图1a:试验(A)中,投予本发明南洋山苏水萃物对肝功能指数GOT/AST的影响结果。
图1b:试验(A)中,投予本发明南洋山苏水萃物对肝功能指数GPT/ALT的影响结果。
图2a~2c:试验(B)中,投予本发明南洋山苏水萃物对肝细胞坏死的影响结果。
具体实施方式
为使本发明的上述及其他目的、特征及优点能更明显易懂,下文特列举本发明的较佳实施例,并配合附图,作详细说明如下:
本发明所述的“南洋山苏(Asplenium australasicum(J.Sm.)Hook.)”,是指铁角蕨科(Aspleniaceae)铁角蕨属(Asplenium)的植物,其新生嫩叶(young emerging frond)常被作为食用菜叶。
本发明的南洋山苏水萃物,可以降低乙醇所造成的肝功能指数升高的现象及减缓乙醇所造成的肝细胞坏死的现象,因而可以应用于制备治疗酒精性肝炎的药物,该南洋山苏水萃物与医药学上可以接受的载剂或赋形剂组合形成医药组合物,其中,该南洋山苏水萃物可以制备成任何方便食用的型式,如锭剂、胶囊、粉剂、粒剂或液剂等,或者将该南洋山苏水萃物与其他食品或饮料组合,以适于食用的形态供生物体以口服方式服用。
本发明的南洋山苏水萃物可以供投予一个所需个体,例如以2.5毫升/公斤体重的剂量投予该所需个体,使该南洋山苏水萃物所含有的活性成分得以于该所需个体体内作用,降低乙醇所造成的肝功能指数升高的现象及减缓乙醇所造成的肝细胞坏死的现象。
其中,该南洋山苏水萃物较佳可以通过包括以下步骤的方法所制得:提供一个南洋山苏样品;以水作为萃取溶剂萃取该南洋山苏样品;及将南洋山苏粗萃液进行浓缩,以获得该南洋山苏水萃物。
详而言之,该南洋山苏样品可以为南洋山苏的成熟老叶(三年以上,背面分布孢子),较佳可以预先将该南洋山苏样品于110~120℃的温度下进行干燥(将100克南洋山苏样品干燥至20克),得到南洋山苏干燥物;此外,该南洋山苏样品也可以预先碎成粉粒(粒径约为1~2mm),以增加该南洋山苏样品与该萃取溶剂的接触表面积,借此提升后续萃取的萃取效率。
举例而言,每4.8公斤的南洋山苏样品能够混合该萃取溶剂,使二者总体积达80公升,并于115~125℃的温度、0.35~0.5Kg/cm2G的压力下进行萃取1.5~3小时,上述萃取也可以重复多次,使该南洋山苏样品所富含的活性成分可以完整溶出于该萃取溶剂,此为本发明所属技术领域中具有通常知识者所广泛应用,在此不加以赘述。
前述的南洋山苏粗萃液可以经过减压浓缩及冷冻干燥,以获得该南洋山苏水萃物,通过此程序,可以使该南洋山苏水萃物的活性成分更加浓缩,因此仅需使用少量的该南洋山苏水萃物即可以发挥最佳疗效。
为证实本发明的南洋山苏水萃物可以降低乙醇所造成的肝功能指数升高的现象及减缓乙醇所造成的肝细胞坏死的现象,遂将每4.8公斤的南洋山苏样品萃取所获得的南洋山苏粗萃液,经过减压浓缩及冷冻干燥获得共800克的南洋山苏水萃物粉末,另外将5克的南洋山苏水萃物粉末溶于20毫升的水后,进行以下试验。
(A)南洋山苏水萃物对肝功能指数的影响
本试验选用雄性Wistar大鼠(200~250g)进行试验,分别以如表1所示的南洋山苏水萃物连续经口灌食各组大鼠4天(每天一次),于第4天经口灌食50%乙醇水溶液,24小时后牺牲各组大鼠,经心脏采血取得血清,以分析各组大鼠的肝功能指数,其结果如图1a、图1b所示。
表1、本试验各组的处理条件。
组别 | 50%乙醇水溶液 | 南洋山苏水萃物 |
第A0组 | - | - |
第A1组 | + | - |
第A2组 | + | 2.5mL/kg |
请参照图1a、图1b所示,浓度为2.5mL/kg的南洋山苏水萃物可以有效降低乙醇所造成的肝功能指数升高的现象(第A2组)。
(B)南洋山苏水萃物对坏死的肝细胞的影响
本试验同样选用雄性Wistar大鼠进行试验,分别以如表2所示的南洋山苏水萃物连续经口灌食各组大鼠4天(每天一次),于第4天经口灌食50%乙醇水溶液,24小时后牺牲各组大鼠,收取肝脏后,切片并进行苏木素─伊红染色(hematoxylin and eosin stain、H&E stain),结果分别如图2a~图2c所示。
表2、本试验各组的处理条件。
组别 | 50%乙醇水溶液 | 南洋山苏水萃物 | 图式 |
第B0组 | - | - | 图2a |
第B1组 | + | - | 图2b |
第B2组 | + | 2.5mL/kg | 图2c |
请参照图2b所示,经口灌食50%乙醇水溶液的第B1组大鼠的肝脏出现大量空泡;而预先经口灌食浓度为2.5mL/kg的南洋山苏水萃物的第B2组大鼠的空泡则有减缓的状况,显示本发明的南洋山苏水萃物可以有效减缓乙醇所造成的肝细胞坏死的现象。
综上所述,本发明的南洋山苏水萃物的用途通过萃取自南洋山苏的活性成分,可以降低乙醇所造成的肝功能指数升高的现象及减缓乙醇所造成的肝细胞坏死的现象,因而可以应用于制备治疗酒精性肝炎的药物,为本发明的功效。
虽然本发明已利用上述较佳实施例公开,但其并非用以限定本发明,本领域技术人员在不脱离本发明的精神和范围之内,相对上述实施例进行各种更动与修改仍属于本发明所保护的技术范畴,因此本发明的保护范围应当以权利要求书所界定为准。
Claims (3)
1.一种南洋山苏水萃物的用途,其特征在于,应用于制备治疗酒精性肝炎的药物,其中,该南洋山苏水萃物以水作为萃取溶剂,于115~125℃的温度、0.35~0.5 Kg/cm2G的压力下萃取一个南洋山苏样品1.5~3小时所获得。
2.如权利要求1所述的南洋山苏水萃物的用途,其特征在于,该南洋山苏水萃物以口服方式投予一个所需个体。
3.如权利要求2所述的南洋山苏水萃物的用途,其特征在于,该南洋山苏水萃物的每天投予该所需个体的剂量为2.5毫升/公斤体重。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106123698 | 2017-07-14 | ||
TW106123698A TWI615146B (zh) | 2017-07-14 | 2017-07-14 | 南洋山蘇水萃物的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109248180A true CN109248180A (zh) | 2019-01-22 |
Family
ID=62016202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810763544.1A Pending CN109248180A (zh) | 2017-07-14 | 2018-07-12 | 南洋山苏水萃物的用途 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN109248180A (zh) |
TW (1) | TWI615146B (zh) |
WO (1) | WO2019014037A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI615146B (zh) * | 2017-07-14 | 2018-02-21 | 景鑫生物科技股份有限公司 | 南洋山蘇水萃物的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103505457A (zh) * | 2012-06-27 | 2014-01-15 | 景鑫生物科技有限公司 | 山苏萃取物及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132021A1 (en) * | 1997-04-30 | 2002-09-19 | Ilya Raskin | Elicited plant products |
EP1370272A1 (en) * | 2001-03-02 | 2003-12-17 | Biopharmacopae Design International Inc. | Inhibitors of extracellular proteases |
JP2004123657A (ja) * | 2002-10-07 | 2004-04-22 | Noevir Co Ltd | 皮膚外用剤 |
US20140363526A1 (en) * | 2013-06-06 | 2014-12-11 | Bioved Pharmaceuticals, Inc. | Synergistic formulation of plant extracts for hepatic and adrenal disorders |
TWI615146B (zh) * | 2017-07-14 | 2018-02-21 | 景鑫生物科技股份有限公司 | 南洋山蘇水萃物的用途 |
-
2017
- 2017-07-14 TW TW106123698A patent/TWI615146B/zh not_active IP Right Cessation
-
2018
- 2018-07-05 WO PCT/US2018/040849 patent/WO2019014037A1/en active Application Filing
- 2018-07-12 CN CN201810763544.1A patent/CN109248180A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103505457A (zh) * | 2012-06-27 | 2014-01-15 | 景鑫生物科技有限公司 | 山苏萃取物及其用途 |
Non-Patent Citations (2)
Title |
---|
刘基柱: "《药用植物野外识别手册》", 31 May 2015, 羊城晚报出版社 * |
韩淑花等: "《甘露消毒丹》", 31 January 2013, 中国医药科技出版社 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019014037A1 (en) | 2019-01-17 |
TW201907938A (zh) | 2019-03-01 |
TWI615146B (zh) | 2018-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102406205B (zh) | 牡蛎多糖果汁饮料 | |
CN103446174B (zh) | 低聚甘露糖醛酸在制备预防和治疗酒精性肝损伤的药物、保健品或饮食补充剂中的应用 | |
CN102349934A (zh) | 一种虫草菌丝体有效成分的提取工艺 | |
CN103992416A (zh) | 金蝉花多糖及其在制备神经保护和抗衰老药物中的应用 | |
CN106084087A (zh) | 一种瓜蒌多糖的制备方法 | |
CN103446165B (zh) | 低聚古罗糖醛酸在制备预防和治疗酒精性肝损伤的药物、保健品或饮食补充剂中的应用 | |
CN102068494A (zh) | 对化学性肝损伤有治疗作用的保健胶囊及其制备方法 | |
CN102293802B (zh) | 一种治疗心血管疾病的药物组合物及其制备方法 | |
CN109248180A (zh) | 南洋山苏水萃物的用途 | |
CN102512438A (zh) | 太子参多糖在预防、治疗糖尿病和保健食品中的应用 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN107412254A (zh) | 金线莲多糖提取物的应用 | |
CN104758309B (zh) | 树莓多糖降血糖的用途 | |
CN101683338A (zh) | 毛钩藤碱在制备治疗心肌损伤药物中的用途 | |
CN102336803A (zh) | 七叶皂苷提取物的纯化制备方法 | |
CN109125458A (zh) | 橘叶提取物在制备治疗/预防自身免疫性睾丸炎药物中的应用 | |
CN109248181A (zh) | 南洋山苏水萃物的用途 | |
CN110680840B (zh) | 小黑药提取物在制备降血脂药物中的应用 | |
CN103565960B (zh) | 一种半仿生提取技术制备枳椇子提取物的方法 | |
CN102861121A (zh) | 一种瓜蒌皮注射制剂及其制备方法 | |
CN101947290A (zh) | 一种具有滋阴作用的药物 | |
CN101683337B (zh) | 柯楠因在制备治疗心肌损伤性心脏病药物中的用途 | |
CN105998101B (zh) | 维药斯米孜·欧提提取物在制备肝保护药物和保健品中的应用 | |
CN104547026A (zh) | 一种丹参叶三七提取物的制备方法及其应用 | |
CN103238847A (zh) | 含有绞股蓝的保健食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190122 |
|
WD01 | Invention patent application deemed withdrawn after publication |